Earnings summaries and quarterly performance for Generation Bio.
Executive leadership at Generation Bio.
Board of directors at Generation Bio.
AQ
Anthony Quinn
Detailed
Director
CS
Catherine Stehman-Breen
Detailed
Director
CR
Charles Rowland
Detailed
Director
DA
Dannielle Appelhans
Detailed
Director
DN
Donald Nicholson
Detailed
Director
GM
Geoff McDonough
Detailed
Chair of the Board
GC
Gustav Christensen
Detailed
Director
JR
Jason Rhodes
Detailed
Director
JJ
Jeffrey Jonas
Detailed
Director
RC
Ron Cooper
Detailed
Director
Research analysts covering Generation Bio.
Recent press releases and 8-K filings for GBIO.
Generate Biomedicines Files for IPO
GBIO
New Projects/Investments
Listing Issues
- Generate Biomedicines, an AI drug-discovery company, has filed for an IPO on Nasdaq to fund its pipeline.
- The company aims to raise upwards of $100 million in the IPO and has already secured $805 million from preferred stock sales and approximately $110 million from collaborations with Novartis and Amgen.
- Its lead AI-designed anti-TSLP antibody, GB-0895, has advanced into Phase 3 for severe asthma and is also being evaluated in a Phase 1 trial for COPD.
- IPO proceeds will prioritize advancing GB-0895 and two other clinical-stage programs: GB-4362 (an MMAE-directed adjunct antibody) and GB-5267 (a MUC16-targeted CAR-T for ovarian cancer).
2 days ago
GRI Bio Summarizes Full Year 2025 Financial Results and Clinical Progress
GBIO
Earnings
Guidance Update
New Projects/Investments
- GRI Bio reported $8.2 million in cash and cash equivalents as of December 31, 2025, and subsequently raised an additional $6.5 million in gross proceeds in January 2026, strengthening its balance sheet to fund operations into the first quarter of 2027.
- For the full year ended December 31, 2025, the company reported a net loss of $12 million, with research and development expenses increasing to $6.8 million.
- The company announced positive Phase 2a clinical data for its lead program, GRI-0621, in idiopathic pulmonary fibrosis, and is advancing GRI-0803 for autoimmune indications.
3 days ago
Ademi Firm investigates Generation Bio transaction with XOMA Royalty Corporation
GBIO
Legal Proceedings
M&A
Takeover Bid
- The Ademi Firm is investigating Generation Bio (GBIO) for possible breaches of fiduciary duty and other legal violations related to its recently announced transaction with XOMA Royalty Corporation.
- In the transaction, Generation Bio shareholders are expected to receive $4.2913 per share in cash plus one contingent value right (CVR) per share.
- The CVRs will entitle holders to portions of net cash above $29 million at closing, potential savings from Cambridge office lease obligations, and proceeds from Generation Bio's existing license agreement with Moderna.
- The investigation also notes that Generation Bio insiders will receive substantial benefits from change of control arrangements, and the transaction agreement includes a significant penalty for accepting a competing bid, which is being examined for unreasonably limiting other transactions.
Dec 16, 2025, 1:21 AM
Generation Bio Co. to be acquired by XOMA Royalty Corporation
GBIO
M&A
Takeover Bid
- XOMA Royalty Corporation has entered into an agreement to acquire Generation Bio Co. for $4.2913 per share in cash, plus one non-transferable contingent value right (CVR) per share.
- The CVR entitles Generation Bio stockholders to potential payments from net cash exceeding $29 million at closing, savings on Cambridge office lease obligations, and a share of proceeds from Generation Bio's existing license agreement with Moderna (up to 90%) and the ctLNP delivery platform (up to 70%).
- Generation Bio's board of directors unanimously approved the Merger Agreement, and stockholders representing approximately 15% of common stock have signed support agreements to tender their shares.
- The acquisition is expected to close in February 2026.
Dec 15, 2025, 10:00 PM
GRI Bio Announces Positive Phase 2a Clinical Trial Results for IPF Treatment
GBIO
New Projects/Investments
- GRI Bio announced positive topline data from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- The study met its primary endpoint, demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events.
- Secondary endpoints showed improvements in serum biomarkers of collagen turnover, suggesting fibrosis resolution and induction of an alveolar basement membrane repair mechanism.
- GRI-0621 also demonstrated increases in forced vital capacity (FVC), with 39% of treated subjects experiencing an increase in FVC at 12 weeks, compared to 80% of placebo-treated subjects experiencing a decline.
Dec 10, 2025, 9:05 PM
Generation Bio Co. Announces Third Quarter 2025 Financial Results
GBIO
Earnings
Legal Proceedings
M&A
- Generation Bio Co. reported cash, cash equivalents, and marketable securities of $89.6 million as of September 30, 2025, a decrease from $185.2 million as of December 31, 2024.
- The company's net loss for the quarter ended September 30, 2025, was $5.5 million, or $0.82 basic and diluted net loss per share, an improvement compared to a net loss of $15.3 million, or $2.29 basic and diluted net loss per share, for the same period in 2024.
- In August 2025, Generation Bio settled litigation with a landlord, involving a $31.0 million payment and resulting in a $25.5 million gain on lease termination.
- Generation Bio is currently evaluating strategic alternatives to maximize shareholder value.
Nov 5, 2025, 9:12 PM
Generation Bio Co. Announces CEO Transition and Executive Changes
GBIO
CEO Change
Management Change
Executive Compensation
- Geoff McDonough, MD will step down as Chief Executive Officer and President of Generation Bio Co. and become Chair of the Board of Directors, effective October 31, 2025.
- Yalonda Howze, JD, the current Chief Legal Officer, has been appointed Interim Chief Executive Officer and President, effective October 31, 2025.
- Dr. McDonough will receive approximately $700,000 in cash severance, a prorated bonus of approximately $300,000, and acceleration of vesting for 25% of his outstanding unvested equity awards. He will also provide advisory services as a consultant until October 31, 2026, at $500 per hour, with continued equity vesting.
- As Interim CEO, Ms. Howze's annual base salary will be $575,000, with an annual target bonus of 50% of her base salary, prorated for 2025.
- Antoinette Paone (Chief Operating Officer) and Phillip Samayoa (Chief Scientific Officer) will also terminate their employment effective October 31, 2025, and will enter into consulting agreements until October 31, 2026, with hourly fees of $360 and $400, respectively, and continued equity vesting.
Oct 22, 2025, 8:13 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more